Skip to main content
OpenTrials
Completed

NCT Number: NCT03812198

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

This is a phase 1 trial to evaluate the safety, tolerability, and pharmacokinetics of 4 different oral formulations of LEO 32731 in healthy subjects. The trial will be conducted in 3 parts at a single site. Each eligible subject will be enrolled into 1 group only and will participate in 3 treatment periods.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

LEO Pharma Investigational Site

Leeds, United Kingdom

About this study

Part 1 will evaluate the pharmacokinetics of single doses of 4 test formulations of LEO 32731 compared with a reference formulation. Part 2 will evaluate the effect of food on the pharmacokinetics of selected test formulations of LEO 32731. Part 3 will evaluate the tolerability and safety of selected test formulations of LEO 32731 after multiple dosing.

Based on data from Part 1, up to 3 formulations will be taken forward to Part 2. If none of the formulations are considered appropriate to take forward to Part 2, the trial will stop after Part 1. Similarly, based on data from Part 2, up to 2 formulations will be taken forward to Part 3. If none of the formulations are considered appropriate to take forward to Part 3, the trial will stop after Part 2.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Key inclusion criteria:

  • Age 18 to 65 years, inclusive.
  • Body mass index of 18.5 to 29.9 kg/m2, inclusive.
  • In good health, at the discretion of the investigator, as determined by: medical history, physical examination, vital sign assessment (specifically, blood pressure must be within normal reference range), 12-lead ECG, clinical laboratory evaluations, aspartate aminotransferase and alanine aminotransferase not above the upper limit of normal (Gilbert's syndrome is not acceptable).
  • Female subjects of childbearing potential must be willing to use a highly effective form of birth control in conjunction with a barrier method of contraception throughout the trial and for at least 90 days after final follow-up.
  • Male subjects with a female partner of childbearing potential must be willing to use a highly effective form of birth control in conjunction with male barrier method of contraception (i.e. male condom with spermicide) throughout the trial and for at least 90 days after final follow-up.

Key exclusion criteria:

  • Systemic or topical treatment within 14 days prior to first dose administration unless in the opinion of the investigator the medication will not interfere with the trial procedures or compromise safety.
  • Any medications, including St. John's wort, known to chronically alter drug absorption or elimination processes within 30 days prior to first dose administration.
  • Subjects who smoke more than an average of 10 cigarettes per day.
  • History of chronic alcohol or drug abuse within 12 months prior to screening.
  • Subjects with ≥3 bowel movements per day.
  • Any disorder which is not stable and could: Affect the safety of the subject throughout the trial; Influence the findings of the trial; Impede the subject's ability to complete the trial. Examples include but are not limited to cardiovascular, GI, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, immunological, and psychiatric disorders and major physical impairment.

Treatment and study plan

LEO 32731 modified release tablet

Drug

At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.

LEO 32731 blend, hard capsule

Drug

At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

LEO 32731 API, hard capsule

Drug

At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

LEO 32731 soft capsule

Drug

At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

LEO 32731 gastro-resistant capsule

Drug

At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.

LEO 32731

Drug

At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.

Placebo

Other

At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.

Primary outcomes

  1. Part 1. AUC0-∞

    Time frame: Calculated using concentration data collected from predose to 48 hours postdose for each treatment period in Part 1

    AUC0-∞: Area under the plasma concentration-time curve from time 0 extrapolated to infinity

  2. Part 1. Relative bioavailability (F-rel)

    Time frame: Calculated using concentration data collected from predose to 48 hours postdose for each treatment period in Part 1

    F-rel: AUC0 ∞ test formulations/AUC0-∞ reference formulation (derived from the statistical analysis of AUC0-∞)

  3. Part 1. C-max

    Time frame: Calculated using concentration data collected from predose to 48 hours postdose for each treatment period in Part 1

    C-max: Maximum observed plasma concentration

  4. Part 1. t-max

    Time frame: Calculated using concentration data collected from predose to 48 hours postdose for each treatment period in Part 1

    t-max: Time to reach maximum observed plasma concentration

  5. Part 2. AUC0-∞

    Time frame: Calculated using concentration data collected from predose to 72 hours postdose for each treatment period in Part 2

    AUC0-∞: Area under the plasma concentration-time curve from time 0 extrapolated to infinity

  6. Part 2. Relative bioavailability (F-rel)

    Time frame: Calculated using concentration data collected from predose to 72 hours postdose for each treatment period in Part 2

    F-rel: AUC0 ∞ test formulations/AUC0-∞ reference formulation (derived from the statistical analysis of AUC0-∞)

  7. Part 2. C-max

    Time frame: Calculated using concentration data collected from predose to 72 hours postdose for each treatment period in Part 2

    C-max: Maximum observed plasma concentration

  8. Part 2. t-max

    Time frame: Calculated using concentration data collected from predose to 72 hours postdose for each treatment period in Part 2

    t-max: Time to reach maximum observed plasma concentration

  9. Part 3. Number of GI-related AEs and number of subjects with GI-related AEs during the treatment period

    Time frame: From Day 1 (first dose) to Day 19 (end of treatment period) in Part 3

    AEs: adverse events; GI: gastrointestinal

Secondary outcomes

  1. Part 1. Number of GI-related AEs and number of subjects with GI-related AEs during each combination of treatment and period.

    Time frame: 24 days (from first dose in first treatment period until end of last treatment period) in Part 1

    AEs: adverse events; GI: gastrointestinal

  2. Part 1. Number of total AEs and number of subjects with AEs during each combination of treatment and period

    Time frame: 24 days (from first dose in first treatment period until end of last treatment period) in Part 1

    AEs: adverse events

  3. Part 1. Number of subjects with systolic blood pressure in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during each treatment period in Part 1: predose, 4 hours, 24 hours, and 48 hours postdose

    Normal: ≥90 and ≤140 mmHg. Clinical significance of abnormal values as judged by the investigator

  4. Part 1. Number of subjects with diastolic blood pressure in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during each treatment period in Part 1: predose, 4 hours, 24 hours, and 48 hours postdose

    Normal: ≥45 and ≤90 mmHg. Clinical significance of abnormal values as judged by the investigator

  5. Part 1. Number of subjects with pulse rate in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during each treatment period in Part 1: predose, 4 hours, 24 hours, and 48 hours postdose

    Normal: ≥40 and ≤100 beats/minute. Clinical significance of abnormal values as judged by the investigator

  6. Part 1. Number of subjects with body temperature in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during each treatment period in Part 1: predose, 4 hours, 24 hours, and 48 hours postdose

    Normal: ≥35 and ≤37.5°C. Clinical significance of abnormal values as judged by the investigator

  7. Part 1. Number of subjects with PR interval in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening, predose in Treatment period 1, and 48 hours postdose in Treatment period 3 in Part 1

    Normal: ≥120 and ≤220 msec. Clinical significance of abnormal values as judged by the investigator

  8. Part 1. Number of subjects with QRS duration in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening, predose in Treatment period 1, and 48 hours postdose in Treatment period 3 in Part 1

    Normal: ≤120 msec. Clinical significance of abnormal values as judged by the investigator

  9. Part 1. Number of subjects with QTcF interval in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening, predose in Treatment period 1, and 48 hours postdose in Treatment period 3 in Part 1

    QTcF: QT interval corrected for heart rate according to Fridericia's method. Normal: ≤450 msec for males and ≤470 msec for females. Clinical significance of abnormal values as judged by the investigator

  10. Part 1. AUC0-t

    Time frame: Calculated using concentration data collected from predose to 48 hours postdose for each treatment period in Part 1

    AUC0-t: area under the plasma concentration time curve from time 0 to the time of last observed quantifiable concentration

  11. Part 1. t1/2

    Time frame: Calculated using concentration data collected from predose to 48 hours postdose for each treatment period in Part 1

    t1/2: apparent terminal half-life

  12. Part 2. Number of GI-related AEs and number of subjects with GI-related AEs during each combination of treatment and period.

    Time frame: 28 days (from first dose in first treatment period until end of last treatment period) in Part 2

    AEs: adverse events; GI: gastrointestinal

  13. Part 2. Number of total AEs and number of subjects with AEs during each combination of treatment and period

    Time frame: 28 days (from first dose in first treatment period until end of last treatment period) in Part 2

    AEs: adverse events

  14. Part 2. Number of subjects with systolic blood pressure in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during each treatment period in Part 2: predose, 4 hours, 24 hours, and 72 hours postdose

    Normal: ≥90 and ≤140 mmHg. Clinical significance of abnormal values as judged by the investigator

  15. Part 2. Number of subjects with diastolic blood pressure in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during each treatment period in Part 2: predose, 4 hours, 24 hours, and 72 hours postdose

    Normal: ≥45 and ≤90 mmHg. Clinical significance of abnormal values as judged by the investigator

  16. Part 2. Number of subjects with pulse rate in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during each treatment period in Part 2: predose, 4 hours, 24 hours, and 72 hours postdose

    Normal: ≥40 and ≤100 beats/minute. Clinical significance of abnormal values as judged by the investigator

  17. Part 2. Number of subjects with body temperature in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during each treatment period in Part 2: predose, 4 hours, 24 hours, and 72 hours postdose

    Normal: ≥35 and ≤37.5°C. Clinical significance of abnormal values as judged by the investigator

  18. Part 2. Number of subjects with PR interval in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening, predose in Treatment period 1, and 72 hours postdose in Treatment period 3 in Part 2

    Normal: ≥120 and ≤220 msec. Clinical significance of abnormal values as judged by the investigator

  19. Part 2. Number of subjects with QRS duration in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening, predose in Treatment period 1, and 72 hours postdose in Treatment period 3 in Part 2

    Normal: ≤120 msec. Clinical significance of abnormal values as judged by the investigator

  20. Part 2. Number of subjects with QTcF interval in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening, predose in Treatment period 1, and 72 hours postdose in Treatment period 3 in Part 2

    QTcF: QT interval corrected for heart rate according to Fridericia's method. Normal: ≤450 msec for males and ≤470 msec for females. Clinical significance of abnormal values as judged by the investigator

  21. Part 2. AUC0-t

    Time frame: Calculated using concentration data collected from predose to 72 hours postdose for each treatment period in Part 2

    AUC0-t: area under the plasma concentration time curve from time 0 to the time of last observed quantifiable concentration

  22. Part 2. t1/2

    Time frame: Calculated using concentration data collected from predose to 72 hours postdose for each treatment period in Part 2

    t1/2: apparent terminal half-life

  23. Part 3. AUC0-∞

    Time frame: Calculated using concentration data collected from predose to 16 hours postdose on Day 17 in Part 3

    AUC0-∞: Area under the plasma concentration-time curve from time 0 extrapolated to infinity

  24. Part 3. C-max

    Time frame: Calculated using concentration data collected from predose to 16 hours postdose on Day 17 in Part 3

    C-max: Maximum observed plasma concentration

  25. Part 3. t-max

    Time frame: Calculated using concentration data collected from predose to 16 hours postdose on Day 17 in Part 3

    t-max: Time to reach maximum observed plasma concentration

  26. Part 3. AUC0-t

    Time frame: Calculated using concentration data collected from predose to 16 hours postdose on Day 17 in Part 3

    AUC0-t: area under the plasma concentration time curve from time 0 to the time of last observed quantifiable concentration

  27. Part 3. t1/2

    Time frame: Calculated using concentration data collected from predose to 16 hours postdose on Day 17 in Part 3

    t1/2: apparent terminal half-life

  28. Part 3. Number of total AEs and number of subjects with AEs during the treatment period

    Time frame: From Day 1 (first dose) to Day 19 (end of treatment period) in Part 3

    AEs: adverse events

  29. Part 3. Number of subjects with systolic blood pressure in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during the treatment period in Part 3: Days 1, 3, 5, 7, 9, and 11: predose and 4 hours postdose; Day 17: predose, 4 hours, and 12 hours postdose; Day 19 (=48 hours postdose)

    Normal: ≥90 and ≤140 mmHg. Clinical significance of abnormal values as judged by the investigator

  30. Part 3. Number of subjects with diastolic blood pressure in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during the treatment period in Part 3: Days 1, 3, 5, 7, 9, and 11: predose and 4 hours postdose; Day 17: predose, 4 hours, and 12 hours postdose; Day 19 (=48 hours postdose)

    Normal: ≥45 and ≤90 mmHg. Clinical significance of abnormal values as judged by the investigator

  31. Part 3. Number of subjects with pulse rate in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during the treatment period in Part 3: Days 1, 3, 5, 7, 9, and 11: predose and 4 hours postdose; Day 17: predose, 4 hours, and 12 hours postdose; Day 19 (=48 hours postdose)

    Normal: ≥40 and ≤100 beats/minute. Clinical significance of abnormal values as judged by the investigator

  32. Part 3. Number of subjects with body temperature in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during the treatment period in Part 3: Days 1, 3, 5, 7, 9, and 11: predose and 4 hours postdose; Day 17: predose, 4 hours, and 12 hours postdose; Day 19 (=48 hours postdose)

    Normal: ≥35 and ≤37.5°C. Clinical significance of abnormal values as judged by the investigator

  33. Part 3. Number of subjects with PR interval in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during the treatment period in Part 3: Day 1: predose and 4 hours postdose; Days 3, 5, 7, 9, 11, and 17: 4 hours postdose; Day 19 (=48 hours postdose)

    Normal: ≥120 and ≤220 msec. Clinical significance of abnormal values as judged by the investigator

  34. Part 3. Number of subjects with QRS duration in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during the treatment period in Part 3: Day 1: predose and 4 hours postdose; Days 3, 5, 7, 9, 11, and 17: 4 hours postdose; Day 19 (=48 hours postdose)

    Normal: ≤120 msec. Clinical significance of abnormal values as judged by the investigator

  35. Part 3. Number of subjects with QTcF interval in each of the following categories: 'normal', 'abnormal, not clinically significant', 'abnormal, clinically significant'

    Time frame: At screening and during the treatment period in Part 3: Day 1: predose and 4 hours postdose; Days 3, 5, 7, 9, 11, and 17: 4 hours postdose; Day 19 (=48 hours postdose)

    QTcF: QT interval corrected for heart rate according to Fridericia's method. Normal: ≤450 msec for males and ≤470 msec for females. Clinical significance of abnormal values as judged by the investigator

Sponsors and collaborators

Lead sponsor

LEO Pharma

Industry

Registry information

Official study title

A Phase 1, 3-part, Single (Open-label) and Multiple (Double-blind, Placebo-controlled) Oral Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of LEO 32731 Formulations in Healthy Subjects

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Jan 23, 2019
Registry last updated
Jul 1, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.